Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis ; volume:69 ; number:5 ; day:18 ; month:3 ; year:2024 ; pages:1808-1825 ; date:5.2024
Digestive diseases and sciences ; 69, Heft 5 (18.3.2024), 1808-1825, 5.2024
- Urheber
-
Peyrin-Biroulet, L.
Bossuyt, P.
Bettenworth, D.
Loftus, E. V.
Anjie, S. I.
D’Haens, G.
Saruta, M.
Arkkila, P.
Park, H.
Choi, D.
Kim, D- H.
Reinisch, W.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10620-023-08252-1
- URN
-
urn:nbn:de:101:1-2407252111226.108255573474
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Peyrin-Biroulet, L.
- Bossuyt, P.
- Bettenworth, D.
- Loftus, E. V.
- Anjie, S. I.
- D’Haens, G.
- Saruta, M.
- Arkkila, P.
- Park, H.
- Choi, D.
- Kim, D- H.
- Reinisch, W.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Untersuchungen zu Wirkungen von TNFá und des TNFá Blockers Infliximab auf Immunzellen
![Apoptose primärer intestinaler Epithelzellen unter dem Einfluss des TNF-α-Antikörpers [TNF-alpha-Antikörpers] Infliximab](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Apoptose primärer intestinaler Epithelzellen unter dem Einfluss des TNF-α-Antikörpers [TNF-alpha-Antikörpers] Infliximab
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Untersuchungen zu Wirkungen von TNFá und des TNFá Blockers Infliximab auf Immunzellen
Apoptose primärer intestinaler Epithelzellen unter dem Einfluss des TNF-α-Antikörpers [TNF-alpha-Antikörpers] Infliximab
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Untersuchungen zu Wirkungen von TNFá und des TNFá Blockers Infliximab auf Immunzellen
Apoptose primärer intestinaler Epithelzellen unter dem Einfluss des TNF-α-Antikörpers [TNF-alpha-Antikörpers] Infliximab
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era